Exploring Three High Growth Tech Stocks in the United States

In This Article:

The market in the United States has remained flat over the past week but has seen a significant 32% increase over the past year, with earnings expected to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for continued expansion and innovation in alignment with these promising market conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

23.83%

24.32%

★★★★★★

Ardelyx

25.24%

69.64%

★★★★★★

Sarepta Therapeutics

24.00%

42.51%

★★★★★★

Alnylam Pharmaceuticals

22.35%

70.33%

★★★★★★

Clene

78.50%

60.16%

★★★★★★

TG Therapeutics

34.66%

56.98%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 245 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Apellis Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that specializes in discovering, developing, and commercializing therapeutic compounds aimed at inhibiting the complement system for treating autoimmune and inflammatory diseases, with a market cap of approximately $4.41 billion.

Operations: Apellis Pharmaceuticals generates revenue primarily from developing and commercializing proprietary therapeutics, totaling $715.22 million. The company is focused on leveraging its expertise in complement system inhibition to treat autoimmune and inflammatory diseases.

Apellis Pharmaceuticals has showcased significant progress, particularly in its innovative treatments for rare kidney diseases. Recent data from the VALIANT study underscored pegcetacoplan's potential, demonstrating a 68% reduction in proteinuria and stabilization of kidney function. This advancement is critical given the high recurrence rates of disease post-kidney transplant. Financially, Apellis reported a substantial increase in revenue to $196.83 million for Q3 2024, up from $110.4 million year-over-year, with losses narrowing significantly to $57.45 million from $140.24 million. These developments suggest a robust trajectory as the company gears up for new drug applications in early 2025, marking significant strides in addressing unmet medical needs within nephrology and beyond.